Aduro Biotech, Inc. (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 1,815 shares of the business’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $8.01, for a total value of $14,538.15. Following the sale, the executive vice president now owns 75,533 shares of the company’s stock, valued at approximately $605,019.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Aduro Biotech, Inc. (ADRO) traded up $0.10 during mid-day trading on Wednesday, hitting $8.35. The stock had a trading volume of 686,900 shares, compared to its average volume of 403,962. Aduro Biotech, Inc. has a 52 week low of $6.01 and a 52 week high of $15.25.

Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. During the same period in the prior year, the company earned ($0.54) earnings per share. The firm’s quarterly revenue was up .0% on a year-over-year basis. research analysts anticipate that Aduro Biotech, Inc. will post -1.28 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2017/11/15/aduro-biotech-inc-adro-evp-dirk-g-brockstedt-sells-1815-shares.html.

ADRO has been the subject of a number of recent analyst reports. HC Wainwright set a $18.00 price objective on Aduro Biotech and gave the company a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research downgraded Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. BidaskClub downgraded Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Cowen and Company initiated coverage on Aduro Biotech in a report on Tuesday, July 18th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.14.

A number of hedge funds and other institutional investors have recently modified their holdings of ADRO. Harvard Management Co. Inc. acquired a new position in Aduro Biotech during the third quarter valued at approximately $69,418,000. JPMorgan Chase & Co. raised its stake in Aduro Biotech by 283.7% in the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after buying an additional 275,295 shares during the period. Goldman Sachs Group Inc. raised its stake in Aduro Biotech by 330.5% in the first quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock valued at $2,545,000 after buying an additional 181,734 shares during the period. Renaissance Technologies LLC raised its stake in Aduro Biotech by 762.1% in the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock valued at $1,955,000 after buying an additional 160,800 shares during the period. Finally, Nexthera Capital LP bought a new stake in Aduro Biotech in the second quarter valued at approximately $1,767,000. 33.63% of the stock is owned by hedge funds and other institutional investors.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.